mPharma
A pan African health tech building a trusted pharmacy and primary care network to cut medicine prices and improve availability.
Across Africa, the biggest health risk is often not a rare disease. It is a simple lack of access. Pharmacies run out of stock, prices vary wildly between neighborhoods, and families delay treatment because cash is tight.
mPharma started with one idea: medicines should be affordable and reliably available, whatever your city or income. Instead of building one more clinic, it built the plumbing that clinics and pharmacies depend on.
By combining supply chain control, data, and a branded pharmacy network, mPharma aims to make a standard dose cost less and be in stock when a patient needs it.
When access becomes predictable, care becomes possible.
Key Numbers
Note: Latest public company figures as of 2025.
Company Information
mPharma is a technology driven healthcare company that manages medicine supply, pricing, and last mile delivery through partner pharmacies and its Mutti branded points of care. Its goal is to reduce stockouts and lower the cost of essential drugs for everyday patients.
mPharma mission
Leadership
| Role | Name | Background |
|---|---|---|
| Founder | Gregory Rockson | Founded mPharma in 2013, now board chair after 2025 CEO transition |
| CEO | Kwesi Arhin | Appointed in 2025 to lead the next phase of scale and profitability |
| Medical and operations | Country teams | Local pharmacy, hospital, and supply partnerships |
How the Model Works
mPharma links manufacturers, distributors, pharmacies, and patients into one managed network. It uses forecasting and pooled purchasing to keep shelves stocked and prices stable.
What mPharma Controls
Growth and Results
Starting in Ghana, mPharma expanded through acquisitions and partner onboarding in West, East, and Southern Africa. The Mutti network has become the main delivery channel for its model.
Operational Highlights
- Scaled network: from 250+ pharmacies in 2021 to 850+ points of care in 2025
- Pan African reach: active across 9 countries with local teams
- Hospital integration: 155 hospital partners linked to its supply flows
The company restructured in 2023 to focus on core Mutti and supply operations.
Where They Work
mPharma operates a blended footprint of owned and partner pharmacies, with stronger presence in high demand urban corridors.
| Country | Presence | Notes |
|---|---|---|
| Ghana | Core market | Headquarters and dense Mutti network |
| Nigeria | Core market | Expanded through HealthPlus majority stake |
| Kenya | Core market | Chain acquisition and network growth |
| Zambia | Growth market | Mutti pharmacies scaling in cities |
| Malawi | Growth market | Primary care oriented Mutti sites |
| Rwanda, Ethiopia, Uganda, Gabon | Emerging presence | Partner onboarding and service rollout |
Expansion focus since 2024 includes Francophone West Africa.
Funding History
Funding has supported acquisitions, supply infrastructure, and Mutti network build out. Recent rounds signal a shift toward sustainable unit economics.
Main Supporters
Competitive Landscape
The market is fragmented, with many independent pharmacies and uneven distribution. mPharma competes on supply reliability, price stability, and network trust.
| Company | Model | Markets | How mPharma is Different |
|---|---|---|---|
| mPharma | Managed Mutti network Supply platform | 9 countries | Combines pricing, inventory, and branded care sites |
| Large local chains | Retail only | Single markets | mPharma adds pooled supply and standard quality |
| E pharmacies and delivery apps | Online order | Few markets | mPharma is hybrid with physical first point of care |
| Informal drug sellers | Low price, low control | Everywhere | mPharma focuses on safe supply and trust |
Key Lessons for Founders
What can builders learn from mPharma?
- Fix the system, not one clinic. Supply reliability can unlock health outcomes at scale.
- Trust is a product. Standards and consistent pricing build loyalty in care.
- Blend digital and physical. Apps matter, but pharmacies are where decisions happen.
- Acquire to accelerate. Buying chains can be faster than greenfield growth.
- Refocus when needed. The 2023 reset protected the core model.
• Network, countries, hospitals, patients from mPharma official 2025 company figures
• 2021 network baseline from mPharma impact reporting and World Economic Forum profile
• Funding totals from Tracxn, Citi round disclosures, and Launch Base Africa reporting
• Leadership transition from 2025 news coverage
Data checked November 2025